The diagnostics company Gradientech today announces to have started its third FDA 510(k) clinical study site in the US for the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST). Following successful pre-clinical evaluation studies of the QuickMIC system in the US, a breakthrough device designation by the FDA and the …